Live feed07:00:00·36dPRReleaseArvinas Announces Positive Phase 1 Data for ARV-102 Showing Greater Than 50% LRRK2 Degradation in the CSF of Patients with Parkinson's Disease Treated for 28 DaysARVN· Arvinas Inc.Health CareOriginal source
